Key Takeaways:
Novo Nordisk has begun a late-stage study of lower doses of its oral semaglutide (Wegovy) pill to find the lowest effective dose for weight loss.
The Phase 3 trial is registered in the U.S. government's clinical trials database, according to the listing posted Aug. 19. The Danish drugmaker is evaluating whether reduced doses of the once-daily pill can still deliver meaningful weight reduction while improving tolerability and lowering the cost per patient.
The study extends Novo's push to broaden access to its GLP-1 franchise beyond the injectable versions of semaglutide sold as Wegovy and Ozempic. Oral semaglutide, approved in the U.S. as Rybelsus for type 2 diabetes, is being developed for weight management under the Wegovy brand.
A lower-dose oral option could expand the addressable patient population for the weight-loss drug, which has faced supply constraints and pricing scrutiny since demand surged. It would also sharpen Novo's competitive position against Eli Lilly, which is advancing its own oral GLP-1 candidate in late-stage development.
The GLP-1 class has become one of the most contested in the drug industry, with Novo and Lilly racing to capture a market projected in the tens of billions of dollars. Wegovy and Ozempic rank among the best-selling medicines globally, and an oral formulation is seen as a way to reach patients who avoid injections.
Finding the lowest effective dose matters for more than cost. Gastrointestinal side effects such as nausea and vomiting are the most common reason patients stop GLP-1 treatment, and a smaller dose could improve adherence while preserving weight-loss benefit. It could also ease pressure on manufacturing capacity, which has constrained supply of the injectable versions.
Novo did not disclose the trial's target enrollment, dosing schedule, or expected completion date in the registration. The company has not yet said when it expects to report results or file for regulatory approval of a lower-dose formulation.
The move shows Novo is betting that a more flexible dosing strategy can capture patients who struggle with side effects or cost at higher doses. Investors will watch for enrollment updates and interim data from the trial, which could shape the competitive outlook for the GLP-1 market in the coming years.
This article is for informational purposes only and does not constitute investment advice.
